Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

The cAMP-phosphodiesterase PDE4B2 controls peroxisome proliferator-activated receptor γ expression and the initiation of adipogenesis in 3T3-L1 cells

Fiedler E., Boyd A., Irelan D., Rachek LI., Abou Saleh L., Richter W.

Animal Study on Type 2 Diabetes, published in Am J Physiol Endocrinol Metab (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Am J Physiol Endocrinol Metab (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41083256
PMCID
PMC12870952
DOI
10.1152/ajpendo.00215.2025
Citations
3

Abstract (original English)

The cyclic adenosine monophosphate (cAMP)-phosphodiesterase 4 (PDE4) family comprises four genes that together are expressed as ∼25 protein variants. Nonselective PAN-PDE4 inhibition exerts various metabolic benefits, including reduced body weight and adiposity in humans and animals, but the role of individual PDE4s in mediating these effects remains ill-defined. We noticed that the hormonal induction of adipogenesis in 3T3-L1 preadipocytes increased the mRNA and protein expression of a single PDE4 variant, PDE4B2. Conversely, its siRNA-mediated knockdown markedly suppressed adipogenic differentiation and lipid accumulation, suggesting a critical role for PDE4B2 in adipogenesis. The onset of adipogenesis is well understood and involves the consecutive upregulation of proadipogenic transcription factors CCAAT-enhancer-binding proteins (C/EBPs) C/EBPδ, C/EBPβ, and C/EBPα, which ultimately induce peroxisome proliferator-activated receptor γ (PPARγ) as the master regulator of adipogenesis. PDE4B knockdown potently suppressed the upregulation of C/EBPα and PPARγ expression, thereby curbing the early steps in adipogenic differentiation. Mirroring its antiadipogenic effects in 3T3-L1 cells, PDE4B ablation in mice produces a lean phenotype characterized by reduced adipose tissue weight and reduced expression of C/EBPα and PPARγ. Although PPARγ agonists promote weight gain, they are als

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
3T3-L1 CellsAdipocytesAnimalsMiceCCAAT-Enhancer-Binding ProteinsCCAAT-Enhancer-Binding Protein-alphaPPAR gammaCell DifferentiationMaleAdipogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research